PARKIN deletions or loss of function mutations have been identified in ovarian, breast, bladder, and lung cancers (this topic has recently been thoroughly reviewed elsewhere) (97); additionally, mice null for PARKIN develop spontaneous macroscopic hepatic tumors (98). This evidence concerns the gene PRKN and lung carcinoma.